BLA 125156 · Genentech
Lucentis
Ranibizumab · Injection, Injection · Vascular Endothelial Growth Factor Inhibitor
NovelBreakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Jun 30, 2006
Approved uses
10
Original approval plus efficacy supplements
Registered trials
538
153 Phase 3, 12 recruiting
FAERS reports
26,326
22,469 serious, 5,093 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 21, 2025.
LUCENTIS is indicated for the treatment of patients with: LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascularization (mCNV)
Mechanism: Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF 110 . VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 15, 2017 Supplement 114 · Efficacy · priority review LabelLetterReview
- Jan 5, 2017 Supplement 111 · Efficacy · priority review LabelLetter
- Feb 6, 2015 Supplement 106 · Efficacy · priority review ReviewLetterLabel
- Nov 25, 2014 Supplement 105 · Efficacy LetterLabel
- Feb 27, 2014 Supplement 94 · Efficacy LabelLetter
- Feb 6, 2013 Supplement 81 · Efficacy LabelLetter
- Aug 10, 2012 Supplement 76 · Efficacy LabelLetter
- Jun 22, 2010 Supplement 53 · Efficacy · priority review ReviewLabelLetter
- Apr 23, 2008 Supplement 11 · Efficacy
- Jun 30, 2006 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
2 products under this application
- LUCENTIS · RANIBIZUMAB 6MG/ML · Injectable, Injection · Prescription
- LUCENTIS · RANIBIZUMAB 10MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ranibizumab" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)Pivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT00251459 · 5,000 participants · Start Nov 2005
Drug: rhuFab V2 (ranibizumab) · For: Choroidal Neovascularization; Age-related Macular Degeneration
- Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00637377 · 1,240 participants · Start Apr 2008 · Primary completion Sep 2010
Drug: Ranibizumab; Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) and 2 more · For: Macular Degeneration
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Rosario, Argentina · 189 sites in all
- Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT00509795 · 1,217 participants · Start Aug 2007 · Primary completion Sep 2010
Drug: ranibizumab; aflibercept injection (VEGF Trap-Eye, BAY86-5321) and 2 more · For: Macular Degeneration
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 188 sites in all
- Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin TrialPivotal-lookingCompleted
University of PennsylvaniaAcademic, hospital or other
NCT00593450 · 1,208 participants · Start Feb 2008 · Primary completion Dec 2010
Drug: ranibizumab; bevacizumab · For: Age Related Macular Degeneration
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 59 sites in all
- A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)Pivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT00891735 · 1,097 participants · Start Jul 2009 · Primary completion Aug 2011
Drug: Ranibizumab · For: Age-related Macular Degeneration
Sites: Phoenix, Arizona; Tucson, Arizona; Arcadia, California · 99 sites in all
- A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPivotal-lookingActive, not recruiting
EyeBiotech Ltd.Industry
NCT06957080 · 1,054 participants · Start Apr 16, 2025 · Primary completion Jan 11, 2027
Drug: Remigromig; Ranibizumab · For: Diabetic Macular Edema (DME)
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 164 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01986907 · 1,049 participants · Start Mar 4, 2014 · Primary completion Jun 15, 2016
Drug: ranibizumab · For: Wet Age Related Macular Degeneration
Sites: Alessandria, Italy; Casale Monferrato, Italy; Ancona, Italy · 101 sites in all
Kagawa UniversityAcademic, hospital or other
NCT02321267 · 1,000 participants (planned) · Start Dec 2014 · Primary completion Dec 2024
Drug: ranibizumab, aflibercept, pegaptanib, verteporphin · For: Macular Disease
Sites: Hiragi, Japan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death3,801
- visual acuity reduced2,891
- off label use1,729
- visual impairment1,666
- cerebrovascular accident1,239
- drug ineffective1,210
- blindness1,047
- eye haemorrhage1,047
- vision blurred1,035
- no adverse event1,028
- eye pain961
- retinal haemorrhage801
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 52 |
| 2007 | 563 |
| 2008 | 351 |
| 2009 | 691 |
| 2010 | 1,150 |
| 2011 | 2,457 |
| 2012 | 2,382 |
| 2013 | 2,727 |
| 2014 | 2,172 |
| 2015 | 1,268 |
| 2016 | 1,251 |
| 2017 | 2,543 |
| 2018 | 1,575 |
| 2019 | 1,288 |
| 2020 | 1,266 |
| 2021 | 1,039 |
| 2022 | 853 |
| 2023 | 748 |
| 2024 | 1,233 |
| 2025 | 458 |
| 2026 | 258 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lucentis (Ranibizumab)
2024 spending
$2.6M
Beneficiaries
332
1,203 claims
Per beneficiary
$7,924
$34,768.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,157,221 |
| 2021 | $2,756,595 |
| 2022 | $5,385,256 |
| 2023 | $3,838,736 |
| 2024 | $2,630,671 |
Part B: Lucentis (Ranibizumab) · HCPCS J2778
2024 spending
$129M
Beneficiaries
33,741
144,995 claims
Per beneficiary
$3,821
2024 ASP limit $158.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,113,124,781 |
| 2021 | $1,044,929,993 |
| 2022 | $795,501,259 |
| 2023 | $386,040,635 |
| 2024 | $128,919,305 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ranibizumab for neovascular age-related macular degeneration.
Rosenfeld PJ, Brown DM, Heier JS, et al. · N Engl J Med 2006 · Clinical Trial, Phase III, Multicenter Study
- Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS, Brown DM, Chong V, et al. · Ophthalmology 2012 · Clinical Trial, Phase III, Comparative Study
- Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Wells JA, Glassman AR, Ayala AR, et al. · N Engl J Med 2015 · Comparative Study, Multicenter Study
- Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
Martin DF, Maguire MG, Ying GS, et al. · N Engl J Med 2011 · Comparative Study, Multicenter Study
- Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis.
Watkins C, Paulo T, Bührer C, et al. · Adv Ther 2023 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis.
Ortiz-Seller A, Martorell P, Barranco H, et al. · Surv Ophthalmol 2024 · Comparative Study, Systematic Review
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.